Literature DB >> 34101813

Selection of Adjuvant Endocrine Therapy for Women With Breast Cancer in Menopausal Transition: Is It Simpler Than We Thought?

Shaveta Vinayak1,2,3, Nancy E Davidson1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34101813      PMCID： PMC8562953          DOI： 10.1093/jnci/djab092

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  15 in total

1.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Authors:  Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2007-01-02       Impact factor: 44.544

2.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Authors:  Beat Thürlimann; Aparna Keshaviah; Alan S Coates; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch
Journal:  N Engl J Med       Date:  2005-12-29       Impact factor: 91.245

3.  Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

Authors:  G Viale; M M Regan; P Dell'Orto; M G Mastropasqua; E Maiorano; B B Rasmussen; G MacGrogan; J F Forbes; R J Paridaens; M Colleoni; I Láng; B Thürlimann; H Mouridsen; L Mauriac; R D Gelber; K N Price; A Goldhirsch; B A Gusterson; A S Coates
Journal:  Ann Oncol       Date:  2011-02-18       Impact factor: 32.976

4.  20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Authors:  Hongchao Pan; Richard Gray; Jeremy Braybrooke; Christina Davies; Carolyn Taylor; Paul McGale; Richard Peto; Kathleen I Pritchard; Jonas Bergh; Mitch Dowsett; Daniel F Hayes
Journal:  N Engl J Med       Date:  2017-11-09       Impact factor: 91.245

5.  Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

Authors:  Henning Mouridsen; Anita Giobbie-Hurder; Aron Goldhirsch; Beat Thürlimann; Robert Paridaens; Ian Smith; Louis Mauriac; John F Forbes; Karen N Price; Meredith M Regan; Richard D Gelber; Alan S Coates
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

6.  Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.

Authors:  José Alejandro Pérez-Fidalgo; Susana Roselló; Elisa García-Garré; Esther Jordá; Paloma Martín-Martorell; Begoña Bermejo; Isabel Chirivella; Cecilia Guzman; Ana Lluch
Journal:  Breast Cancer Res Treat       Date:  2009-07-03       Impact factor: 4.872

7.  Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Authors:  Paul E Goss; James N Ingle; Kathleen I Pritchard; Nicholas J Robert; Hyman Muss; Julie Gralow; Karen Gelmon; Tim Whelan; Kathrin Strasser-Weippl; Sheldon Rubin; Keren Sturtz; Antonio C Wolff; Eric Winer; Clifford Hudis; Alison Stopeck; J Thaddeus Beck; Judith S Kaur; Kate Whelan; Dongsheng Tu; Wendy R Parulekar
Journal:  N Engl J Med       Date:  2016-06-05       Impact factor: 91.245

8.  Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era.

Authors:  Alessandro Marco Minisini; Jessica Menis; Francesca Valent; Claudia Andreetta; Barbara Alessi; Gaetano Pascoletti; Andrea Piga; Gianpiero Fasola; Fabio Puglisi
Journal:  Anticancer Drugs       Date:  2009-07       Impact factor: 2.248

9.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

10.  Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.

Authors:  Gwen M H E Dackus; Katarzyna Jóźwiak; Gabe S Sonke; Elsken van der Wall; Paul J van Diest; Sabine Siesling; Michael Hauptmann; Sabine C Linn
Journal:  J Natl Cancer Inst       Date:  2021-11-02       Impact factor: 13.506
View more
  1 in total

1.  RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.

Authors:  Natalie Klar; Sylvia Adams
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 11.816
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.